Larimar Therapeutics, Inc.

NASDAQ: LRMR · Healthcare · Biotechnology

PublicHQ Bala Cynwyd, PA · MontgomeryCIK 0001374690Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

37D

FH 33DQ 38GM —SS 60

v0.1 · 55/100 weight · provisional

↑ market scale, Altman-Z · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$165.7M

Employees

Market cap

$279.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02019

Net income-$165.7M-$165.7M2025

Operating income-$172.5M-$172.5M2025

Total assets$145.8M$145.8M2025

Liabilities$67.8M$67.8M2025

Equity$78.1M$78.1M2025

Revenue trend

FY2018 – FY2019 · USD

FY18

FY19

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Larimar Therapeutics, Inc. booked $0 in FY2019 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Altimmune, Inc.54D ALX Oncology Holdings Inc.37D Prelude Therapeutics Incorporated36D Perspective Therapeutics, Inc.46D

Neighbors

Montgomery →

Cencora, Inc.$321.3B84B+Toll Brothers, Inc.$11.0B69B Madrigal Pharmaceuticals, Inc.$958.4M64C Essential Utilities, Inc.$2.5B71B SEI Investments Company$2.3B82B+Globus Medical, Inc.$2.9B86A

Key facts

CEOCarole S. Ben-Maimon

SectorHealthcare

IndustryBiotechnology

HeadquartersBala Cynwyd, PA

ExchangeNASDAQ: LRMR

Employees65

IPO date2014-06-19

Latest filings

8-K2026-06-29 8-K2026-05-19 10-Q2026-05-14 8-K2026-05-14 DEF 14A2026-04-20 8-K2026-03-19 10-K2026-03-19 8-K2026-03-09

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.